Preliminary efficacy data from Phase 1/2 dose expansion cohort show durable responses and tumor shrinkage in a PD-(L)1 resistant “hot” tumor ...
4don MSN
If the past four decades have taught us anything about HIV, it's to adjust our expectations—despite enormous progress in ...
BOSTON, March 28, 2025 (GLOBE NEWSWIRE) -- Sensei Biotherapeutics, Inc. (Nasdaq: SNSE), a clinical stage biotechnology company focused on the discovery and development of next-generation ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results
Feedback